Texas Pharmaceutical Services S-4 Registration of securities issued in business combination transactions

Exhibit 12.1

US Oncology, Inc.

Computation of Ratio of Earnings to Fixed Charges

											Pro Forma
											Year		Six Months
											Ended		Ended
	Year Ended December 31,						Six Months Ended June 30,				December 31,		June 30,
	2006		2007		2008		2008		2009		2008		2009
					(dollars in thousands)
Net income (loss) before income taxes	71,922		18,252		(360,815	)	(370,237	)	(2,595	)	(376,060	)	(12,773	)
Less: Net income before taxes attributable to noncontrolling interests	(2,388	)	(3,619	)	(3,324	)	(1,732	)	(1,703	)	(3,324	)	(1,703	)
Net income (loss) before income taxes attributable to the Company	69,534		14,633		(364,139	)	(371,969	)	(4,298	)	(379,384	)	(14,476	)
Fixed Charges:
Interest expense incurred	93,770		96,342		93,857		47,146		45,657		109,102		55,835
Interest portion of lease expense	26,033		29,349		32,607		15,913		17,220		32,607		17,220
Total fixed charges	119,803		125,691		126,464		63,059		62,877		141,709		73,055
Net income before income taxes and fixed charges attributable to the Company	189,337		140,324		(237,675	)	(308,910	)	58,579		(237,675	)	58,579
Less: capitalized interest	(900	)	(1,000	)	(1,100	)	(513	)	(551	)	(1,100	)	(551	)
Earnings	188,437		139,324		(238,775	)	(309,423	)	58,028		(238,775	)	58,028
Ratio of earnings to fixed charges	1.6 x		1.1 x		N/A	*	N/A	*	N/A	*	N/A	*	N/A	*
Amount by which earnings before fixed charges insufficient to cover fixed charges	—		—		(365,239	)	(372,482	)	(4,849	)	(380,484	)	(15,027	)

(1) The ratio of earnings to fixed charges was calculated by dividing (i) net income (loss) before income taxes and fixed charges by (ii) fixed charges which consist of interest expense incurred, including amortization of debt expense and discount, and one-third of rental expense, which approximates the interest portion of our rental expense.